Biosyent enters agreement to purchase Tibelia assets for up to EUR 2.8M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 20 2024
0mins
BioSyent Acquisition: BioSyent Pharma Inc. has acquired assets to supply Tibelia, a tibolone-based hormone replacement therapy, from Novalon SA and Mithra Pharmaceuticals for up to EUR 2.8 million, including intellectual property and distribution rights.
Market Presence: Tibolone has been used for over 30 years to treat menopause symptoms, with BioSyent marketing it in Canada since 2020; Novalon SA reported approximately EUR 2.1 million in revenue from Tibelia in 2023.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
